Dextran Series Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a controlled molecular-weight family of dextran polymers and iron-dextran complex manufactured by fermentation of sucrose with Leuconostoc mesenteroides, followed by hydrolysis and ethanol fractionation. The product line includes Dextran 40, Dextran 60, Dextran 70, and iron dextran complex, with weight-average molecular mass designations of 40,000 Da, 60,000 Da, and 70,000 Da for the non-complexed polymers. The material is supplied as a white to off-white spray-dried powder with high water solubility and low ethanol solubility. It is manufactured under 21 CFR 210 and 21 CFR 211 current good manufacturing practice and is tested against the current United States Pharmacopeia and European Pharmacopoeia monographs for dextran and iron dextran, including size-exclusion chromatography for molecular mass distribution, bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14, and residual solvent limits according to USP <467>. The API is intended for use in injectable plasma volume expanders, injectable iron supplementation, tablet and capsule wet granulation, dry powder blends, feed premixes, and aqueous solution preparations.

Which molecular weight grades are specified for parenteral and solid oral use?

Molecular mass determines renal clearance, colloid osmotic effect, solution viscosity, and film formation. Dextran 40 is specified for parenteral use where rapid renal excretion and short-term plasma volume support are required; Dextran 70 is specified for prolonged colloidal support and higher oncotic pressure per gram. Dextran 60 is an intermediate grade used in solid oral formulations and some injection preparations where a balance between binding and dissolution is required. Iron dextran complex is not a simple molecular weight grade; it is a macromolecular complex in which ferric iron is bound to dextran-derived carbohydrate chains, and it is specified for intramuscular or injectable iron supplementation. The following table summarizes the product models and the critical use-related variables.

For each model, the release specifications include molecular weight distribution parameters determined by high-performance size-exclusion chromatography with multi-angle laser light scattering. The ratio of weight-average molecular mass to number-average molecular mass is controlled because it directly affects renal clearance and solution rheology. The aqueous solution viscosity at 25 °C is likewise lot-controlled; low-molecular-weight grades are in the low single-digit mPa·s range for 10% w/v solutions, and values increase with molecular weight and total solids content. Published data for the exact viscosity limits of every veterinary premix configuration is limited, but the manufacturing control strategy relies on compendial viscosity or intrinsic viscosity methods rather than single-point measurements for the parenteral grades.

Because the product is intended for multiple veterinary dosage forms, the release specifications differentiate parenteral grades from oral and premix grades. Parenteral grades require bacterial endotoxin and particulate matter control, while oral and premix grades emphasize loss on drying, particle size distribution, and microbial limits. The same carbohydrate backbone is maintained across grades; only the molecular mass and iron complexation are varied.

Formulation Behavior Across Tablets, Injections, Powders, Granules, Premixes, and Solutions

Parenteral formulations are typically prepared as a 10% w/v dextran 40 injection or a 6% w/v dextran 70 injection in isotonic sodium chloride or lactated Ringer's vehicle. The powder is dissolved under low-speed agitation at 20–25 °C; high-shear mixing above 6 m/s tip speed is avoided because excessive air entrainment and localized heating can shear the polymer and reduce molecular weight. The solution is filtered through a 0.22 µm sterilizing-grade membrane filter before terminal sterilization at 121 °C for 15 min. A holding time below 4 h between dissolution and sterilization is maintained to limit microbial proliferation. Osmolality is determined by freezing-point depression according to USP <785>, and subvisible particulate matter is tested according to USP <788>. In veterinary practice, dextran 40 and dextran 70 are differentiated by their species-specific effect on oncotic pressure and urine output; published data for some exotic veterinary species is limited, and dose selection is based on surrogate canine or equine plasma expansion data.

For iron dextran complex, the critical difference is the presence of ferric iron bound to dextran. The complex is sensitive to autoclaving and is often sterilized by membrane filtration rather than terminal heat; if terminal heat is used, the thermal cycle is limited to 121 °C for 15 min only after confirming that free iron remains below the monograph limit. Free iron limit is tested according to the current USP iron dextran monograph, and pH is controlled to maintain complex stability.

In solid oral dosage forms, dextran functions as a rapidly dissolving binder and film-forming agent. It is incorporated in the wet mass at 2–5% w/w of the dry granulate. The binder solution is prepared at 5–10% w/v solids, and its viscosity remains below 20 mPa·s at 25 °C to prevent nozzle blockage in top-spray fluid-bed granulators. Granules are dried to a loss-on-drying endpoint of 2–4% w/w before compression. Tablet breaking force is monitored according to USP <1217>; the accepted range is formulation-specific, but hard intragranular particles above 850 µm are typically milled before lubrication because they reduce content uniformity. Dextran does not require moisture pre-conditioning when the packaging line is maintained below 60% RH; above that value, the powder becomes tacky and can bridge over tablet press feed frames.

For dry powder and premix production, dextran is blended with carriers or active species in diffusion mixers. The particle size distribution is controlled because dextran’s moisture sorption alters flowability in high-humidity environments. Sifters with 40–60 mesh screens are used to disperse agglomerates. Blending time is determined by assay uniformity; significant lot-to-lot variation in particle size above 150 µm can produce segregation in low-dose premixes. Production-scale behavior indicates that fluid-bed drying at inlet air temperatures exceeding 55 °C can cause surface discoloration and particle fusion; therefore, drying is performed at lower temperatures with longer residence times. Solutions for oral or feed use are prepared by cold dissolution with agitation; a clear to slightly opalescent solution forms. Autoclaving at acidic pH below 3.0 accelerates depolymerization, and formulations are buffered to pH 4.5–6.5 before heat sterilization. Use of strong oxidizing agents in cleaning cycles can degrade residual dextran films and produce colored decomposition products; rinse water conductivity is monitored after cleaning to avoid cross-contamination.

Control of bacterial endotoxin is a critical release parameter for the parenteral grades. The raw material is tested by kinetic chromogenic Limulus amebocyte lysate method according to USP <85> and Ph. Eur. 2.6.14, with pass/fail limits aligned to the intended dose volume and species-specific maximum dose. In-house data from production-scale batches show that endotoxin levels and bioburden are influenced by the handling of the powder in classified areas; transfer lines and cyclone separators used after spray drying are maintained under ISO 14644-1:2015 Class 8 or better. Residual moisture is determined by Karl Fischer titration according to USP <921>, with typical release limits for dry powder maintained below 5.0% w/w. Elemental impurities are controlled according to USP <232> and USP <233>. Batch-to-batch molecular weight drift is tracked by SEC-MALS and by rheological comparison of 10% w/v aqueous solutions.

Specific optical rotation at 589 nm is controlled in the +195° to +201° range for a 1% w/v aqueous solution at 25 °C. This parameter provides a rapid identity check and can detect contamination by reducing sugars or incorrect molecular weight fractions. The method is executed according to Ph. Eur. 2.2.7.

Production-scale batch records include raw material sucrose source, fermentation yield, hydrolysis time, ethanol fractionation cuts, spray drying inlet and outlet temperatures, and final sieve analysis. These parameters are reviewed during release because the dextran molecular mass distribution is sensitive to fermentation and hydrolysis conditions. The manufacturer’s batch-specific certificate of analysis is required to confirm the molecular mass distribution, because fermentation and hydrolysis conditions can vary between suppliers. Published data for the exact hydrolysis time and ethanol fractionation cut ranges for every veterinary grade is limited; therefore, the release specification rather than the nominal grade should be used when developing a stability-critical injection.

When high-shear wet granulation is applied to Dextran 40, what process limits control batch uniformity?

High-shear wet granulation with a top-driven impeller and side chopper is used for veterinary tablet formulations requiring rapid binder distribution. For Dextran 40, the process window is defined by impeller tip speed, water addition rate, and final wetness. At impeller tip speeds above 6 m/s, local shear heating can form hard granules and reduce porosity, producing tablets with longer disintegration times. A safer operating range is 2–4 m/s impeller tip speed with chopper speed below 1,500 rpm. Binder solution is added at 2–4 mL/min/kg of dry mass through a peristaltic pump with a nozzle positioned above the moving powder bed. Endpoint is determined by a torque or power consumption curve; wet mass moisture content is targeted at 8–12% w/w and confirmed by loss-on-drying at 105 °C. Wet granulates are milled through a conical mill fitted with a 0.8 mm screen; oversize material above 850 µm is re-milled. The dried granules are compressed within 24 h after drying, because dextran can absorb atmospheric moisture and raise the effective water activity to a level that reduces compactability.

Batch failures on production twin-screw lines have been observed when the dextran feed is not gravimetrically controlled; variations above 5% in dextran feed rate cause wetness swings and alter the granule size distribution. Where a twin-screw granulator with an L/D ratio of 25:1 is used, the powder feed is maintained within ±2% of set point and the liquid-to-solid ratio is controlled by mass flow meters. Published data for continuous wet granulation of veterinary dextran formulations is limited, but the same moisture and shear limits apply to the wetting section.

Relative to hydroxyethyl starch, the dextran series has a lower degree of molar substitution and a more defined molecular mass distribution when produced by controlled fermentation and ethanol fractionation. Hydroxyethyl starch carries hydroxyethyl substituents that prolong intravascular persistence but can accumulate in tissues after repeated administration; dextran is excreted primarily by renal mechanisms, with a higher proportion of Dextran 40 removed within 24 h. Compared with gelatin, dextran is free of animal-derived collagen and does not carry the same prion transmission risk. Compared with povidone as a tablet binder, dextran forms a lower-viscosity aqueous solution at an equivalent 10% w/v aqueous concentration and has a lower glass transition temperature, which affects drying and film formation. However, dextran is more hygroscopic than povidone at relative humidity above 60%, requiring tighter humidity controls during granule storage and compression.

Relative to pregelatinized starch, dextran generates clear aqueous films and does not require heating to hydrate; the absence of gelatinization temperature reduces processing energy input. But dextran can interfere with certain blood glucose and blood typing assays, so its use as an injectable in diagnostic settings is restricted. In feed premixes, dextran is distinguishable from maltodextrin by its higher weight-average molecular mass and its lack of reducing sugar content; this reduces Maillard browning potential in heat-treated feeds but increases solution viscosity when compared with maltodextrin at the same concentration. Published comparative efficacy data in veterinary species is limited for some of these distinctions; the selection between dextran and alternative colloids should be based on species-specific regulatory dossiers and available hematocrit, coagulation, and renal function data.

Operational boundaries include the avoidance of strong oxidizing agents such as persulfates or hypochlorite in cleaning and formulation, protection from moisture above 60% RH, and control of terminal sterilization pH to 4.5–6.5. The dextran series is incompatible with strongly acidic conditions below pH 3.0 during heat sterilization because acid-catalyzed hydrolysis reduces molecular mass and alters colloidal osmotic behavior. Powder-handling areas are maintained below 60% RH; dry powder transfer is performed with low conveying air velocities because the spray-dried particles have a low bulk density and can generate dust. For solid oral and premix operations, cleaning validation should include assay for residual reducing sugar, because degraded dextran can leave sticky residues on contact surfaces.